NCT00004981

Safety and Effectiveness of Three Anti-HIV Drugs Combined in One Pill (Trizivir)

A Phase IIIB Randomized, Multicenter Study of the Efficacy and Safety of Combivir 1 Tablet Po Bid Plus Ziagen 300mg Po Bid Versus an Abacavir 300mg/Lamivudine 150mg/Zidovudine 300mg Combination Tablet Po Bid, Administered for 24 Weeks in Subjects With HIV-1 Infection

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 230 (planned)
• Sponsor: Glaxo Wellcome · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to look at the safety and effectiveness of a pill called Trizivir that is a combination of three anti-HIV drugs (zidovudine, lamivudine, and abacavir). Zidovudine and lamivudine are often given combined in one pill (Combivir). In this study, Trizivir will be compared to Combivir plus abacavir.

Detailed description

Patients are randomized to receive either the triple combination tablet (Trizivir) or to receive Combivir plus abacavir as a separate tablet. Patients take their study medications for 24 weeks.

Conditions

• HIV Infections

Interventions

Type	Name	Description
DRUG	Abacavir sulfate, Lamivudine and Zidovudine
DRUG	Lamivudine/Zidovudine
DRUG	Abacavir sulfate

Timeline

• First posted: 2001-08-31
• Last updated: 2005-06-24

Locations

25 sites across 1 country: United States